Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Oncology
285 Articles Available
1
12
Can't find what you're looking for? Try our
advanced search
.
M&A
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
PR-M07-19-NI-038
Phase III
GSK Announces Positive Headline Results in Phase 3 PRIMA Study of ZEJULA (niraparib) For Patients with Ovarian Cancer
PR-M07-19-NI-039
Clinical Results
Positive Results for Colon Cancer Drug Drove Pfizer’s Purchase of Array BioPharma
PAO-M07-19-NI-017
Alliance
Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
PR-M07-19-NI-027
FDA Approval
FDA Grants Additional Myeloma Approval to J&J’s Darzalex
PAO-M07-19-NI-014
FDA Approval
Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)
PR-M07-19-NI-015
Phase II
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
PR-M07-19-NI-016
Oncology
Imfinzi Improves Survival in the Phase III CASPIAN Trial in 1st-line Extensive-stage Small Cell Lung Cancer
PR-M07-19-NI-003
Biosimilar Approval
Herceptin Biosimilar Approved in the U.S.
PAO-M06-19-NI-017
FDA Approval
FDA Approves Pembrolizumab for Metastatic Small Cell Lung Cancer
PR-M06-19-NI-038
Immune Markers
Using Immune Markers to Identify Precancerous Cells
PAO-M06-19-NI-015
Leadership
Flatiron Health Appoints Cancer Researcher and Pharmaceutical Executive Dr. Michael Vasconcelles as Chief Medical Officer
PR-M06-19-NI-026
Drug Development
Over 1000 Cancer Cell Therapies in Development
PAO-M06-19-NI-003
Financing
Thrive Earlier Detection Gets Funding from Third Rock to Develop Cancer Detection Tech
PAO-M06-19-NI-001
Finance
SAGA Raises 40 Million SEK (€3.7 Million) to Advance Ultrasensitive Cancer Liquid Biopsies
PR-M06-19-NI-009
Research
New Model of Mitosis Could Facilitate Cancer Research
PAO-M05-19-NI-036
Presentation
Cytonus Therapeutics to Present CA-IL12 Breast Cancer Data at the 2019 BIO International Convention
PR-M05-19-NI-086
FDA Approval
FDA Approves First PI3K Inhibitor for Breast Cancer
PR-M05-19-NI-084
FDA Approval
FDA Approves REVLIMID® (Lenalidomide) in Combination With Rituximab for the Treatment of Follicular Lymphoma or Marginal Zone Lymphoma
PR-M05-19-NI-085
Approval
Triple Combination Treatments for Multiple Myeloma Approved in Europe
PAO-M05-19-NI-027
Artificial Intelligence
A Promising Step Forward for Predicting Lung Cancer From Google
PR-M05-19-NI-077
Oncology
Cancer’s New Foes—Novel Oncology Approaches in the Battle Against Cancer
PAP-Q2-2019-CL-020
Endpoint
Array Biopharma Announces Braftovi + Mektovi + Cetuximab Meet Primary Endpoints in Metastatic Colorectal Cancer
PR-M05-19-NI-069
M&A
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
PR-M05-19-NI-067
1
12
»
